Reports

Amid Ukraine-Russia crisis, our analysts and industry experts are closely monitoring the markets and working hard to identify, gather and timely deliver analysis of the impact of the situation and the impact that it has on various markets. All our reports are updated with the latest impact on the market before being sent out to our customers.

Global Rheumatoid Arthritis Therapeutics Market Share, Size, Growth, Analysis; By Product Type: Biologics, Non-Biologics; By Sales Type: Prescription, Over-the-Counter (OTC); By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online; Regional Analysis; Competitive Landscape; Key Trends and Developments in the Market; 2023-2028

Global Rheumatoid Arthritis Therapeutics Market Outlook

The global market for rheumatoid arthritis therapeutics witnessed a market valuation of over USD 58.71 billion in 2022. The global rheumatoid arthritis therapeutics market is anticipated to grow at a CAGR of 2.70% from 2023-2028, driven by increasing prevalence and diagnosis of rheumatoid arthritis.

 

Key Trends in the Market

Rheumatoid arthritis or RA is an auto-immune disorder, a condition in which a person's immune system identifies one's cellular and organ makeup as antigenic entities, resulting in the synthesis of antibodies against one's own body. The disease tends to attack the linings of the joints leading to bone abrasion, joint inflammation, and severe pain. If left untreated, the disease could spread across various organs, which initially affect the joints of fingers and toes. Compared to osteoarthritis, rheumatoid arthritis could also deleteriously affect the eyes, lungs, heart, kidneys, salivary glands, and other vital organs.

 

  • Rheumatoid arthritis therapeutics sees the involvement of Janus-Kinase inhibitors and Tumour Necrosis Factor involvement in drugs as the primary evangelists of the rheumatoid arthritis therapeutics market globally. Moreover, a plethora of drugs innovated to cater to the disease bolsters the firm hold of the market.
  • Disease-modifying antirheumatic drugs (DMARDs), the primary counter-medicines to combat the disease, are maintaining a strong position in the market, despite the introduction of novel drugs.
  • A surge in the obese population, increasing awareness concerning rheumatic disorders, and the rising geriatric population have significantly contributed to the rheumatoid arthritis therapeutics market.
  • Biopharmaceuticals have been and will be one of the most substantial market drivers for the global rheumatoid arthritis market in the years to come. Biopharmaceuticals would fortify sales in the forthcoming years, having played vital roles in eradicating the disease's severity across many countries. Although the drugs are quite expensive as they are still in the market skimming period, market penetration will assuage the high prices once the firmness grows.

 

Global Rheumatoid Arthritis Market Analysis

Based on the product type, the market can be segmented into biologics, and non-biologics. The non-biologics segment is further subdivided into non-steroidal anti-inflammatory drugs (NSAIDs), and synthetic disease-modifying antirheumatic drugs (SDMARDs). Based on sales type, the market is bifurcated into prescription and over-the-counter (OTC).

 

On the basis of distribution channel, the market could be branched into hospital pharmacies, retail pharmacies, and online. The regional markets can be divided into North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.

 

The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis. The report gives a detailed analysis of the following key players in the global rheumatoid arthritis therapeutics market, covering its competitive landscape and the latest developments like mergers, acquisitions, investments and expansion plans.

 

  • Pfizer Inc.
  • Amgen Inc.
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd
  • UCB SA.
  • Gilead Sciences, Inc.
  • Others

 

Market Share by Product Type

Rheumatoid arthritis therapeutics has seen a distended disruption across the world pinned to the change in lifestyle that has exacerbated the underlying symptoms. Owing to this, medications and prophylaxis have seen a motley of options of biologics and non-biologics. Biologics have taken a significant chunk as a prophylactic alternative over the years.

 

Biologics have surpassed the non-biologics in the rheumatoid arthritis therapeutics market behind despite their frugal costs and budget-friendly advantage over biologics. The dominance could be ligated to the therapeutic adeptness of biologics as per various rheumatoid arthritis patients.

 

However, the non-biologics couldn't be wholly uprooted as it has been in the therapeutic market significantly longer than biologics. Moreover, not everyone can afford the advanced treatments of biologics; therefore, non-biologics find its user database cemented with the proletarian spectrum of the population.

 

Market Share by Region

Rheumatoid arthritis therapeutics have been witnessing colossal growth in North America due to the highest reported disease cases. Moreover, the increasing awareness and health consciousness among people have significantly contributed to the dominant share of the region in the rheumatoid arthritis therapeutics market. Also, the vast budget share in the arena of rheumatoid arthritis therapeutics equally raises its market share.

 

Europe has seen significant propellants in the form of novel drugs innovation, advanced healthcare alternatives to grapple with the disease, and an increment in the cases. In the Asia Pacific, the stanchioning infrastructure of healthcare, increasing awareness, and high adoption of biologics have catalysed the therapeutic market.

 

Contrary to the developing strides in North America, Europe, and Asia Pacific, the rheumatoid arthritis therapeutics market coverage hasn't matched the pace in Latin America, the Middle East, and Africa. However, growth could be anticipated after a few years on the grounds of increased awareness.

 

Competitive Landscape

Pfizer Inc., headquartered in New York, United States, was founded in 1849. It has been instrumental in elevating the global pharmaceutical and therapeutic markets with its innovation and substantial league of drugs. The company covers a phenomenal market share across a vast gamut of therapeutics for reducing cholesterol, inflammation, and so on. It has been a major contributor to the expansion of therapeutics for rheumatoid arthritis.

 

Amgen Inc. is based out of California in the United States, and was founded in 1980. A leading biotechnology organisation, Amgen Inc., caters to oncology, bone health, cardiovascular disease, nephrology, neuroscience, and inflammation. The focus area of inflammation considers relevant disorders that give rise to inflammatory disorders, such as rheumatoid arthritis. It’s biologics category counters the disease and its aftermath.

 

Bristol-Myers Squibb Company is headquartered in New York, United States, and has been a vital contributor to the pharmaceutical and healthcare industry since its inception in 1989. The company is a merger between Bristol-Myers and Squibb and has made significant breakthroughs in neurology, haematology, cardiovascular diseases, and immunology, among others. Immunology forms the basis of the company's study and research endeavours of rheumatoid arthritis therapeutics.

 

Other market players include F. Hoffmann-La Roche Ltd, UCB SA, and Gilead Sciences, Inc., among others.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2022
Historical Period 2018-2022
Forecast Period 2023-2028
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Product Type
  • Sales Type
  • Distribution Channel
  • Region
Breakup by Product Type
  • Biologics
  • Non-Biologics
Breakup by Sales Type
  • Prescription
  • Over-the-Counter (OTC)
Breakup by Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online
Breakup by Region
  • North America
    • United States of America 
    • Canada
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Others
  • Asia Pacific
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • Others
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • United Arab Emirates
    • Nigeria
    • South Africa
    • Others
Market Dynamics
  • SWOT
  • Porter's Five Forces
  • Key Indicators for Demand
  • Key Indicators for Price
Competitive Landscape
  • Market Structure
  • Company Profiles
    • Company Overview
    • Product Portfolio
    • Demographic Reach and Achievements
    • Certifications
Companies Covered
  • Pfizer Inc.
  • Amgen Inc.
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd
  • UCB S.A.
  • Gilead Sciences, Inc.
  • Others

 

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.

1    Preface 
2    Report Coverage – Key Segmentation and Scope
3    Report Description

    3.1    Market Definition and Outlook
    3.2    Properties and Applications
    3.3    Market Analysis
    3.4    Key Players
4    Key Assumptions   
5    Executive Summary

    5.1    Overview
    5.2    Key Drivers
    5.3    Key Developments  
    5.4    Competitive Structure
    5.5    Key Industrial Trends
6    Market Snapshot
    6.1    Global
    6.2    Region
7    Opportunities and Challenges in the Market
8    Global Rheumatoid Arthritis Therapeutics Market Analysis

    8.1    Key Industry Highlights
    8.2    Global Rheumatoid Arthritis Therapeutics Historical Market (2018-2022) 
    8.3    Global Rheumatoid Arthritis Therapeutics Market Forecast (2023-2028)
    8.4    Global Rheumatoid Arthritis Therapeutics Market by Product Type
        8.4.1    Biologics 
            8.4.1.1    Market Share
            8.4.1.2    Historical Trend (2018-2022)
            8.4.1.3    Forecast Trend (2023-2028)
        8.4.2    Non-Biologics 
            8.4.2.1    Market Share
            8.4.2.2    Historical Trend (2018-2022)
            8.4.2.3    Forecast Trend (2023-2028)
            8.4.2.4    Breakup by Type
                8.4.2.4.1    Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) 
                8.4.2.4.2    Synthetic Disease-Modifying Antirheumatic Drugs (SDMARDs) 
                8.4.2.4.3    Others
    8.5    Global Rheumatoid Arthritis Therapeutics Market by Sales Type
        8.5.1    Prescription
            8.5.1.1    Market Share
            8.5.1.2    Historical Trend (2018-2022)
            8.5.1.3    Forecast Trend (2023-2028)
        8.5.2    Over-the-Counter (OTC)
            8.5.2.1    Market Share
            8.5.2.2    Historical Trend (2018-2022)
            8.5.2.3    Forecast Trend (2023-2028)
    8.6    Global Rheumatoid Arthritis Therapeutics Market by Distribution Channel
        8.6.1    Hospital Pharmacy 
            8.6.1.1    Market Share
            8.6.1.2    Historical Trend (2018-2022)
            8.6.1.3    Forecast Trend (2023-2028)
        8.6.2    Retail Pharmacy 
            8.6.2.1    Market Share
            8.6.2.2    Historical Trend (2018-2022)
            8.6.2.3    Forecast Trend (2023-2028)
        8.6.3    Online
            8.6.3.1    Market Share
            8.6.3.2    Historical Trend (2018-2022)
            8.6.3.3    Forecast Trend (2023-2028)
    8.7    Global Rheumatoid Arthritis Therapeutics Market by Region
        8.7.1    North America
            8.7.1.1    Market Share
            8.7.1.2    Historical Trend (2018-2022) 
            8.7.1.3    Forecast Trend (2023-2028)
        8.7.2    Europe
            8.7.2.1    Market Share
            8.7.2.2    Historical Trend (2018-2022) 
            8.7.2.3    Forecast Trend (2023-2028)
        8.7.3    Asia Pacific
            8.7.3.1    Market Share
            8.7.3.2    Historical Trend (2018-2022) 
            8.7.3.3    Forecast Trend (2023-2028)
        8.7.4    Latin America
            8.7.4.1    Market Share
            8.7.4.2    Historical Trend (2018-2022) 
            8.7.4.3    Forecast Trend (2023-2028)
        8.7.5    Middle East and Africa
            8.7.5.1    Market Share
            8.7.5.2    Historical Trend (2018-2022) 
            8.7.5.3    Forecast Trend (2023-2028)
9    North America Rheumatoid Arthritis Therapeutics Market Analysis
    9.1    United States of America 
        9.1.1    Market Share
        9.1.2    Historical Trend (2018-2022) 
        9.1.3    Forecast Trend (2023-2028)
    9.2    Canada
        9.2.1    Market Share
        9.2.2    Historical Trend (2018-2022) 
        9.2.3    Forecast Trend (2023-2028)
10    Europe Rheumatoid Arthritis Therapeutics Market Analysis
    10.1    United Kingdom
        10.1.1    Market Share
        10.1.2    Historical Trend (2018-2022) 
        10.1.3    Forecast Trend (2023-2028)
    10.2    Germany
        10.2.1    Market Share
        10.2.2    Historical Trend (2018-2022) 
        10.2.3    Forecast Trend (2023-2028)
    10.3    France
        10.3.1    Market Share
        10.3.2    Historical Trend (2018-2022) 
        10.3.3    Forecast Trend (2023-2028)
    10.4    Italy
        10.4.1    Market Share
        10.4.2    Historical Trend (2018-2022) 
        10.4.3    Forecast Trend (2023-2028)
    10.5    Others
11    Asia Pacific Rheumatoid Arthritis Therapeutics Market Analysis
    11.1    China
        11.1.1    Market Share
        11.1.2    Historical Trend (2018-2022) 
        11.1.3    Forecast Trend (2023-2028)
    11.2    Japan
        11.2.1    Market Share
        11.2.2    Historical Trend (2018-2022) 
        11.2.3    Forecast Trend (2023-2028)
    11.3    India
        11.3.1    Market Share
        11.3.2    Historical Trend (2018-2022) 
        11.3.3    Forecast Trend (2023-2028)
    11.4    ASEAN
        11.4.1    Market Share
        11.4.2    Historical Trend (2018-2022) 
        11.4.3    Forecast Trend (2023-2028)
    11.5    Australia
        11.5.1    Market Share
        11.5.2    Historical Trend (2018-2022) 
        11.5.3    Forecast Trend (2023-2028)
    11.6    Others
12    Latin America Rheumatoid Arthritis Therapeutics Market Analysis
    12.1    Brazil
        12.1.1    Market Share
        12.1.2    Historical Trend (2018-2022) 
        12.1.3    Forecast Trend (2023-2028)
    12.2    Argentina
        12.2.1    Market Share
        12.2.2    Historical Trend (2018-2022) 
        12.2.3    Forecast Trend (2023-2028)
    12.3    Mexico
        12.3.1    Market Share
        12.3.2    Historical Trend (2018-2022) 
        12.3.3    Forecast Trend (2023-2028)
    12.4    Others
13    Middle East and Africa Rheumatoid Arthritis Therapeutics Market Analysis
    13.1    Saudi Arabia
        13.1.1    Market Share
        13.1.2    Historical Trend (2018-2022) 
        13.1.3    Forecast Trend (2023-2028)
    13.2    United Arab Emirates
        13.2.1    Market Share
        13.2.2    Historical Trend (2018-2022) 
        13.2.3    Forecast Trend (2023-2028)
    13.3    Nigeria
        13.3.1    Market Share
        13.3.2    Historical Trend (2018-2022) 
        13.3.3    Forecast Trend (2023-2028)
    13.4    South Africa
        13.4.1    Market Share
        13.4.2    Historical Trend (2018-2022) 
        13.4.3    Forecast Trend (2023-2028)
    13.5    Others
14    Market Dynamics
    14.1    SWOT Analysis
        14.1.1    Strengths
        14.1.2    Weaknesses
        14.1.3    Opportunities
        14.1.4    Threats
    14.2    Porter’s Five Forces Analysis
        14.2.1    Supplier’s Power
        14.2.2    Buyer’s Power
        14.2.3    Threat of New Entrants
        14.2.4    Degree of Rivalry
        14.2.5    Threat of Substitutes
15    Competitive Landscape
    15.1    Market Structure
    15.2    Company Profiles
        15.2.1    Pfizer Inc.
            15.2.1.1    Company Overview
            15.2.1.2    Product Portfolio
            15.2.1.3    Demographic Reach and Achievements
            15.2.1.4    Certifications 
        15.2.2    Amgen Inc. 
            15.2.2.1    Company Overview
            15.2.2.2    Product Portfolio
            15.2.2.3    Demographic Reach and Achievements
            15.2.2.4    Certifications
        15.2.3    Bristol-Myers Squibb Company 
            15.2.3.1    Company Overview
            15.2.3.2    Product Portfolio
            15.2.3.3    Demographic Reach and Achievements
            15.2.3.4    Certifications
        15.2.4    F. Hoffmann-La Roche Ltd
            15.2.4.1    Company Overview
            15.2.4.2    Product Portfolio
            15.2.4.3    Demographic Reach and Achievements
            15.2.4.4    Certifications
        15.2.5    UCB S.A.
            15.2.5.1    Company Overview
            15.2.5.2    Product Portfolio
            15.2.5.3    Demographic Reach and Achievements
            15.2.5.4    Certifications 
        15.2.6    Gilead Sciences, Inc.
            15.2.6.1    Company Overview
            15.2.6.2    Product Portfolio
            15.2.6.3    Demographic Reach and Achievements
            15.2.6.4    Certifications
        15.2.7    Others
16    Key Trends and Developments in the Market


List of Key Figures and Tables

1.    Global Rheumatoid Arthritis Therapeutics Market: Key Industry Highlights, 2018 and 2028
2.    Global Rheumatoid Arthritis Therapeutics Historical Market: Breakup by Product Type (USD Million), 2018-2022
3.    Global Rheumatoid Arthritis Therapeutics Market Forecast: Breakup by Product Type (USD Million), 2023-2028
4.    Global Rheumatoid Arthritis Therapeutics Historical Market: Breakup by Sales Type (USD Million), 2018-2022
5.    Global Rheumatoid Arthritis Therapeutics Market Forecast: Breakup by Sales Type (USD Million), 2023-2028
6.    Global Rheumatoid Arthritis Therapeutics Historical Market: Breakup by Distribution Channels (USD Million), 2018-2022
7.    Global Rheumatoid Arthritis Therapeutics Market Forecast: Breakup by Distribution Channels (USD Million), 2023-2028
8.    Global Rheumatoid Arthritis Therapeutics Historical Market: Breakup by Region (USD Million), 2018-2022
9.    Global Rheumatoid Arthritis Therapeutics Market Forecast: Breakup by Region (USD Million), 2023-2028
10.    North America Rheumatoid Arthritis Therapeutics Historical Market: Breakup by Country (USD Million), 2018-2022
11.    North America Rheumatoid Arthritis Therapeutics Market Forecast: Breakup by Country (USD Million), 2023-2028
12.    Europe Rheumatoid Arthritis Therapeutics Historical Market: Breakup by Country (USD Million), 2018-2022
13.    Europe Rheumatoid Arthritis Therapeutics Market Forecast: Breakup by Country (USD Million), 2023-2028
14.    Asia Pacific Rheumatoid Arthritis Therapeutics Historical Market: Breakup by Country (USD Million), 2018-2022
15.    Asia Pacific Rheumatoid Arthritis Therapeutics Market Forecast: Breakup by Country (USD Million), 2023-2028
16.    Latin America Rheumatoid Arthritis Therapeutics Historical Market: Breakup by Country (USD Million), 2018-2022
17.    Latin America Rheumatoid Arthritis Therapeutics Market Forecast: Breakup by Country (USD Million), 2023-2028
18.    Middle East and Africa Rheumatoid Arthritis Therapeutics Historical Market: Breakup by Country (USD Million), 2018-2022
19.    Middle East and Africa Rheumatoid Arthritis Therapeutics Market Forecast: Breakup by Country (USD Million), 2023-2028
20.    Global Rheumatoid Arthritis Therapeutics Market Structure.

Key Questions Answered in the Report

The market size for global rheumatoid arthritis therapeutics was over USD 58.71 billion in 2022.

The projected CAGR for Rheumatoid Arthritis is around 2.70 % for the forecast period of 2023-2028.

The rise in reported cases of rheumatoid arthritis, introduction of novel drugs in the therapeutic market, and increasing awareness are the major market drivers.

A surge in the usage of biopharmaceuticals, increased accessibility of therapeutics, and breakthroughs in the domain of immunology and anti-inflammatory prophylaxis are the key trends in the market.

The key distribution channels are hospital pharmacies, retail pharmacies, and online channels.

The key players in the global rheumatoid arthritis therapeutics market are Pfizer Inc., Amgen Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, UCB SA, and Gilead Sciences, Inc., among others.

Yes, rheumatoid arthritis doesn't have any permanent cure as of now. Hence, medicines must be taken consistently to mitigate the symptoms.

Rheumatoid arthritis tends to attack the linings of the joints leading to bone abrasion, joint inflammation, and severe pain.

Purchase Full Report

Mini Report

$ 2199     $1799
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 3199     $2999
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Five User License

$ 4199     $3999
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 5199     $4999
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER